Theralase Technologies Inc. (CVE:TLT - Get Free Report)'s share price dropped 1.6% on Friday . The stock traded as low as C$0.29 and last traded at C$0.30. Approximately 41,605 shares traded hands during mid-day trading, a decline of 70% from the average daily volume of 138,317 shares. The stock had previously closed at C$0.31.
Theralase Technologies Stock Performance
The company has a fifty day moving average of C$0.27 and a two-hundred day moving average of C$0.22. The stock has a market capitalization of C$73.66 million, a P/E ratio of -15.00 and a beta of 1.36. The company has a debt-to-equity ratio of 20.58, a current ratio of 1.21 and a quick ratio of 3.40.
Theralase Technologies Company Profile
(
Get Free Report)
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Theralase Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theralase Technologies wasn't on the list.
While Theralase Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
